'What's he going to do? He's going to date his wife more!' Steve Holtzman on Decibel and leaving biotech (again)

Jason Mast

Editor

Steve Holtzman’s last retirement lasted about 4 months. He promises the new one will be a bit longer.

There are big plans for version 2.0: He is going to date his wife.

“That’s the quote: ‘What’s he going to do? He’s going to date his wife more!” Holtzman said in an interview with Endpoints News. “And I’m completely serious.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

'What's he going to do? He's going to date his wife more!' Steve Holtzman on Decibel and leaving biotech (again)

Jason Mast

Editor

Unlock this article instantly by becoming a free subscriber.

Autoimmune patients in CAR-T study see striking improvements across lupus and other diseases

As cash runs tight, bluebird plunges after pricing sickle cell gene therapy well above competitor and failing to win ...

Roche partner touts early allogeneic CAR-T data at #ASH23, but durability remains key question

FDA approves two gene therapies for sickle cell disease, including first that uses CRISPR

How one lab's decadeslong search for the 'holy grail' of sickle cell led to the first CRISPR therapy

Solid Tumors: The Next Frontier of Cancer Immuno-therapy

'What's he go­ing to do? He's go­ing to date his wife more!' Steve Holtz­man on Deci­bel and leav­ing biotech (again)

Jason Mast

Editor

Unlock this article instantly by becoming a free subscriber.

Au­toim­mune pa­tients in CAR-T study see strik­ing im­prove­ments across lu­pus and oth­er dis­eases

As cash runs tight, blue­bird plunges af­ter pric­ing sick­le cell gene ther­a­py well above com­peti­tor and fail­ing to win ...

Roche part­ner touts ear­ly al­lo­gene­ic CAR-T da­ta at #ASH23, but dura­bil­i­ty re­mains key ques­tion

FDA ap­proves two gene ther­a­pies for sick­le cell dis­ease, in­clud­ing first that us­es CRISPR

How one lab's decades­long search for the 'holy grail' of sick­le cell led to the first CRISPR ther­a­py

Sol­id Tu­mors: The Next Fron­tier of Can­cer Im­muno-ther­a­py

'What's he going to do? He's going to date his wife more!' Steve Holtzman on Decibel and leaving biotech (again)

Autoimmune patients in CAR-T study see striking improvements across lupus and other diseases

As cash runs tight, bluebird plunges after pricing sickle cell gene therapy well above competitor and failing to win ...

Roche partner touts early allogeneic CAR-T data at #ASH23, but durability remains key question

FDA approves two gene therapies for sickle cell disease, including first that uses CRISPR

How one lab's decadeslong search for the 'holy grail' of sickle cell led to the first CRISPR therapy

Solid Tumors: The Next Frontier of Cancer Immuno-therapy